38,090 Charles River Laboratories International, Inc. $CRL Shares Acquired by Yousif Capital Management LLC

Key Points

• Yousif Capital Management increased its Charles River Laboratories stake by 721.8% in the third quarter, acquiring 38,090 shares and bringing its holdings to 43,367 shares worth approximately $12.8 million. Institutional investors collectively own 98.91% of the company.
• Several analysts raised their CRL price targets, with Morgan Stanley and Jefferies setting targets of $340; the stock carries a consensus “Moderate Buy” rating and an average target of $302.33.
• Charles River shares rose 1.6% to $345.08, near their 52-week high, after the company exceeded quarterly earnings expectations with adjusted EPS of $3.02 versus the $2.77 consensus, although revenue declined 2.7% year over year.

Yousif Capital Management LLC raised its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 721.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,367 shares of the medical research company's stock after buying an additional 38,090 shares during the period. Yousif Capital Management LLC owned about 0.09% of Charles River Laboratories International worth $12,794,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Amundi lifted its stake in shares of Charles River Laboratories International by 175.2% during the 1st quarter. Amundi now owns 773,315 shares of the medical research company's stock worth $133,397,000 after acquiring an additional 492,301 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Charles River Laboratories International by 14.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company's stock valued at $285,001,000 after acquiring an additional 210,260 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in Charles River Laboratories International by 230.9% in the third quarter. Assenagon Asset Management S.A. now owns 204,537 shares of the medical research company's stock worth $59,044,000 after purchasing an additional 142,716 shares during the period. State of Alaska Department of Revenue lifted its position in shares of Charles River Laboratories International by 2,268.2% during the third quarter. State of Alaska Department of Revenue now owns 111,781 shares of the medical research company's stock worth $32,977,000 after purchasing an additional 107,061 shares during the last quarter. Finally, Ranger Investment Management L.P. bought a new stake in shares of Charles River Laboratories International during the first quarter worth $12,198,000. Institutional investors own 98.91% of the company's stock.

Insider Buying and Selling

In related news, EVP Victoria L. Creamer sold 4,179 shares of the firm's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the sale, the executive vice president owned 30,051 shares of the company's stock, valued at $7,788,017.16. This trade represents a 12.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director James C. Foster sold 33,561 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the completion of the transaction, the director directly owned 31,596 shares in the company, valued at approximately $9,478,800. The trade was a 51.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 94,127 shares of company stock valued at $26,776,516 over the last ninety days. Company insiders own 1.30% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently commented on CRL. Deutsche Bank Aktiengesellschaft upped their price target on shares of Charles River Laboratories International from $300.00 to $320.00 and gave the stock a "buy" rating in a report on Friday, September 25th. Morgan Stanley boosted their price objective on shares of Charles River Laboratories International from $300.00 to $340.00 and gave the company an "overweight" rating in a research report on Monday, October 12th. BNP Paribas Exane set a $250.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Citigroup reaffirmed a "buy" rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Finally, Jefferies Financial Group lifted their price target on shares of Charles River Laboratories International from $305.00 to $340.00 and gave the company a "buy" rating in a research note on Monday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $302.33.

Charles River Laboratories International Stock Up 1.6%

Shares of Charles River Laboratories International stock traded up $5.42 during trading on Friday, hitting $345.08. 822,279 shares of the stock traded hands, compared to its average volume of 1,091,356. The firm has a market cap of $16.47 billion, a P/E ratio of -71.15, a price-to-earnings-growth ratio of 3.17 and a beta of 1.40. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. Charles River Laboratories International, Inc. has a 52-week low of $146.20 and a 52-week high of $351.21. The stock's fifty day simple moving average is $294.35 and its 200 day simple moving average is $233.22.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. During the same period in the previous year, the company posted $3.12 earnings per share. The firm's quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities analysts predict that Charles River Laboratories International, Inc. will post 11.38 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.